Feature | Women's Health | October 03, 2014

GE Healthcare’s SenoClaire to Invigorate U.S. Breast Tomosynthesis Market

Hologic's Selenia Dimensions system

October 3, 2014 — The recent approval of GE Healthcare’s SenoClaire by the U.S. Food and Drug Administration (FDA) will end Hologic’s monopoly of the U.S. digital breast tomosynthesis (DBT) market, offering greater choice for hospitals and patients, according to an analyst with research and consulting firm GlobalData.

Niharika Midha, MSc, GlobalData’s analyst covering medical devices, says that SenoClaire has become only the second DBT system available in the United States and will compete directly with Hologic’s pioneer product, Selenia Dimensions, which has controlled the market since 2011.

According to GlobalData’s estimates, the U.S. is expected to see a significant rise in DBT unit sales, with a compound annual growth rate (CAGR) of 36.4 percent between 2013 and 2020. In addition, DBT is expected to contribute a massive 82 percent toward U.S. breast imaging market revenues by 2020, making this a highly lucrative space for diagnostic imaging players.

“Due to this positive outlook, other companies are also working towards FDA approval for their DBT systems. For example, Siemens Healthcare filed an application for its system, Mammomat Inspiration with DBT option, in June this year,” Midha said.

The analyst notes the two approved DBT devices differ significantly in their mechanisms of acquiring 3-D data sets. Selenia Dimensions acquires 15 images over a 15-degree scan angle, and is capable of providing both 3-D mediolateral oblique (MLO) and 3-D craniocaudal (CC) views of the breast, while SenoClaire captures nine images over 25 degrees to form a 3-D MLO view of the breast. It is unclear whether this device also allows acquisition of a 3-D CC view.

In addition, Selenia Dimensions uses a continuous tube motion to capture images, while SenoClaire uses a step-and-shoot motion for the X-ray tube, meaning the gantry comes to a full halt at every X-ray exposure.

Midha continued, “This could mean a higher scan time with SenoClaire than with Selenia Dimensions for the same breast views. It is important to note, however, that a higher scan time does not necessarily mean increased radiation exposure. Irrespective of the differences between the products, GlobalData believes that long-term success will come down to targeted marketing and strategic pricing.”

For more information: www.globaldata.com

Related Content

Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Densitas Enters Platform Partnership With Blackford
News | Breast Density | December 19, 2018
Breast imaging analytics company Densitas Inc. announced the signing of a new Alliance Partner Agreement with Blackford...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch